Concord Biotech Ltd share price headed higher 5.52% to Rs 1378.35 after the company's net profit surged by 20.57% to Rs 69.57 crore, while revenue from operations gained significantly 20.03% to Rs 309.07 crore in Q3FY26 over Q2FY26.

The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, easing 4.06%. It has marginally improved by 3.17% over last one week and dipped slightly by 0.26% in last one month while the market capitalization of Concord Biotech Ltd has inched up 8.72% and 3.39% in the same period respectively.

Profit before tax (PBT) of Concord Biotech Ltd stood at Rs 95.48 crore in Q3 FY26, climbing 11.44% year-on-year, and jumping 21.88% quarter-on-quarter. EBITDA came in at Rs 94 crore, rallying 25.38% YoY and surging by 35.46% sequentially.

Total expenses increased by 15.45% to Rs 223.07 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 63.66 crore, marginally falling by 8.86% YoY, while employee benefits expense was at Rs 52.31 crore, surging 19.87% YoY.

For the TTM ended FY26, revenue from operations contracted by 12.10% to Rs 1054.89 crore, while net profit tanked by 30.25% to Rs 259.23 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 48097% to Rs 315.04 crore, and PBT tumbled by 30.31% to Rs 344.65 crore compared to previous TTM.

The company's consolidated net cash flow from operating activities stood at Rs 266.88 crore in FY26, as against Rs 244.52 crore in FY25.

Concord Biotech Ltd retreated by 5.49% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 13.19% during the same period.